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An Epidemiological Assessment of Lens Opacifications That 
Impaired Vision in Patients Injected with Radium-2241 
D . CHMELEVSKY 
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Federal Republic of Germany 
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A . M . KELLERER 
Institut für Medizinische Strahlenkunde, Universität Würzburg, Versbacher Strasse 5, D-8700 Würzburg, 
Federal Republic of Germany 
CHMELEVSKY, D., MAYS, C . W., SPIESS, H., STEFANI, F. H., AND KELLERER, A. M. An 
Epidemiological Assessment of Lens Opacifications That Impaired Vision in Patients Injected 
with Radium-224. Radial. Res. 115,238-257 (1988). 
The incidence of lens opacifications that impaired vision (cataract) was analyzed among 831 
patients who were injected with known dosages of 224Ra in Germany shortly after World War 
II. The dependence of the incidence on dosage, i.e., injected activity per unit body weight, and 
on time after treatment was determined. The observations are equally consistent with propor-
tionality of the incidence of cataract to the square of dosage or with a linear dependence beyond 
a threshold of 0.5 MBq/kg. The possibility of a linear dependence without threshold was strongly 
rejected (P < 0.001). The analysis of temporal dependences yielded a component that was corre-
lated with the injected amount of 224Ra and a component that was uncorrected. The former 
1 Work performed under Euratom contracts BI-6-D-0083-D (B), BI-6-F-111-D, and BI-D-461-D (B), 
and U.S. Department of Energy contract DE-AC02-76 EV-00119. 
2 Present address: Radiation Epidemiology Branch, Epidemiology & Biostatistics Program, National 
Cancer Institute, Landow Building, Room 3A22, Bethesda, MD 20205. 
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was inferred by a maximum likelihood analysis to increase approximately as the square of the 
time after treatment. The component unrelated to the treatment was found to increase steeply 
with age and to become dominant within the collective of patients between age 50 and 60. The 
relative magnitudes of the two components were such that a fraction of 55 to 60% of the total of 
58 cataracts had to be ascribed to the dose-related incidence. Impaired vision due to cataract 
was diagnosed before age 54 in 25 cases. In terms of injected activity per unit body weight no 
dependence of the sensitivity on age was found; specifically there was no indication of a faster 
occurrence of the treatment-related cataracts in patients treated at older ages. © 1988 Academic 
Press, Inc. 
I. INTRODUCTION 
The lens of the eye has long been recognized to be particularly sensitive to ionizing 
radiations. The history of experimental studies and clinical observations began within 
a few years of Röntgen's discovery of X rays. A bilateral anterior polar cataract in a 
guinea pig exposed to soft X rays was reported (although not ascribed to the exposure) 
in 1897 (7). In 1905 Treutler stated (2): "In an employee of an X-ray laboratory in 
Hamburg I noticed a bilateral posterior polar cataract. According to the statement of 
the patient he had good vision bilaterally before he was employed as an X-ray worker, 
while his visual acuity at the time of the examination was 6/60." 
Dependences of the frequency of cataracts on absorbed dose and on radiation qual-
ity have been determined in various animal studies (3-7). Radiation-induced cata-
racts were reported among the survivors of the atomic bomb explosions in Hiroshima 
and Nagasaki (8-10) and for cyclotron workers (77). Of particular importance have 
been the observations of Merriam and Focht on radiotherapy patients (12, 13). In 
1969 Spiess (14) reported an increased incidence of cataracts in the follow-up study 
of patients injected with 224Ra. Enhanced frequencies of cataracts were also reported 
for dial painters who ingested large activities of 224Ra (75). Additional studies dealt 
with the possible induction of cataracts by other internal emitters (76), with cataracts 
among leukemia patients exposed to high-dose whole-body irradiations (77), and 
with cataracts among radiation workers (18). A recent report includes a comprehen-
sive review of radiation-induced cataracts in man (79). 
The Spiess group of more than 800 patients exposed to 224Ra has been subject to 
a careful follow-up. The resulting data are a unique source of information on the 
deleterious effects of a short-lived a-emitter (20). The completeness of the follow-up 
was achieved through the collaboration, over more than 30 years, among the patients, 
their doctors, and H. Spiess. Contact is still kept with nearly 400 surviving patients. 
Of particular importance has been the analysis of the dose and time dependence of 
the incidence of bone sarcomas (27, 22). The follow-up has also demonstrated other 
severe late radiation effects, such as growth retardation (23), tooth breakage (24), and 
kidney diseases (25). A summary of observations on cataracts, together with clinical 
case descriptions, has been given recently (26), and a strong correlation (P < 0.001) 
was shown between the frequency of cataracts and the injected activity. 
It is the objective of the present report to quantify these results further and to de-
duce the dose and time dependences that underlie the observed correlation. Dosages 
are expressed in terms of the injected activity of 224Ra relative to the body weight of 
the patients.3 It is not possible at present to convert the activity divided by body 
3 The term "dosage" and the symbol A are used for the activity divided by the body weight to avoid 
confusion with absorbed dose, D. 
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weight into absorbed dose in the lens epithelium of the eye. But information from 
animal studies (27) may, in the future, permit a conversion of the injected dosages 
into values of absorbed dose. 
II. METHODS 
From 1945 to about 1952 repeated intravenous injections of 224Ra were given to German children and 
adults, mainly for the intended treatment of tuberculosis and ankylosing spondylitis. In 1952 Spiess began 
a follow-up of these patients, initially by personal contact, hospital examination, and letters. Since 1964 
their health status has been evaluated at about 3-year intervals by questionnaires mailed to the patients 
and with help from their physicians. Details of the procedures have been given earlier (25). 
Initially, there was no reason to assume that injected 224Ra might cause cataracts,4 and the early question-
naires did not specifically deal with vision. However, by 1967 six patients had reported cataracts, and Spiess 
began to suspect that some might be radiation induced (14). Thus, beginning in 1969, the questionnaires 
inquired about problems with vision and the identity of the patient's ophthalmologist. It is, accordingly, 
possible that a few cases might have been missed among those patients who died prior to 1969. 
Subsequently, an increasing number of patients reported lens opacification that impaired vision. Most 
of these were diagnosed when the patients experienced vision problems and consulted their ophthalmolo-
gists. The large majority of patients with lens opacification in one eye also developed an opacification in 
the other eye within a few years. Thus we tabulate the number of patients with cataract, rather than the 
total number of cataracts. 
The classical radiation effect on the lens is a posterior subcapsular cataract, thought to be induced by 
damage to the actively proliferating germinal epithelial cells on the anterior aspect of the lens equator. The 
damaged epithelial cells produce defective lens fibers which accumulate at the posterior pole of the lens, 
creating a cataract, as first described in humans by Treutler in 1905 (2). Until recently there have been, in 
this collective of patients, no sequential ophthalmologic examinations to identify "subclinical1' lens dam-
ages and observe their eventual progression. Such examinations have been initiated for the younger patients 
who are now in their forties. Thus it may be possible, in the years to come, to distinguish clinically in some 
cases between radiation-induced cataracts and other forms of cataracts. 
Among 25 lens opacifications diagnosed before age 54 we have written confirmation by the patient's 
ophthalmologist or a record of cataract extraction for all but 4. For the total of 58 reported diagnoses we 
have such confirmation or the documentation of cataract extraction in 42 cases. In Germany cataract 
extractions are always preceded by a detailed ophthalmological examination, and they are only exception-
ally performed at a visual acuity above 0.1 (20/200). For 11 cases an additional slit-lamp examination and 
documentation was performed at the Munich University Eye Hospital by one of us (F.H.S.). It was then 
found in most cases that the cataracts were located on the posterior pole of the lens and appeared as a 
plaque of conglomerated irregular granules interspersed with vacuoles (26). 
A list of the patients with cataracts is given in the appendix. 
As pointed out earlier (26), no evidence was found that enhanced cataract rates were caused by the trace 
amounts of eosin and colloidal platinum that accompanied most of the 224Ra injections, although an 
influence of this admixture cannot be entirely excluded.5 There is also no indication that males and females 
have different sensitivity to cataract induction. Consequently male and female patients were combined in 
the present analysis. 
Enhanced cataract frequencies have been reported in ankylosing spondylitis patients, and a marked 
association with tuberculosis had been assumed in the past, although it is now considered less likely {28). 
Possible associations with the original disease do not interfere with the subsequent analysis which is con-
cerned with correlations to injected activity, not with overall rates in the tuberculosis and ankylosing sp3n-
4 Ophthalmologists term any opacity of the lens a cataract; the term therefore includes small opacities not 
interfering with vision. However, in the present report it is used to designate a lens opacification sufficieitly 
progressed to impair vision. 
5 It has been pointed out in the earlier study (26) that no enhanced cataract rates were observed folloving 
tatooing of the cornea with platinum salt, or following the use in the United States in the 1930s of substan-
tially larger doses of eosin (Rose Bengal) for liver-function tests in about a million patients. 
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TABLE I 
Synopsis of Data through 1986 
241 
Mean age* 
Number of Mean At first At last dosage3 
Patients Cataracts injection follow-up At cataract (MBq/kg) 
All adults 627 44 38.7(10.8) 61.1 (11.7) 59.5(12.7) 0.551 (0.397) 
Spondylitis 365 24 41.3(9.5) 63.1 (10.0) 62.6(11.5) 0.379 (0.265) 
Tuberculosis 218 19 33.5(10.6) 58.0(13.1) 56.2(13.3) 0.858(0.598) 
Other 44 1 43.1 (12.6) 60.5(13.5) 48.0 (—) 0.457 (0.333) 
Male adults 468 33 39.3(10.2) 61.5(11.1) 58.9(12.3) 0.489 (0.401) 
Spondylitis 344 22 41.2 (9.4) 62.9(10.1) 62.2(11.8) 0.376 (0.265) 
Tuberculosis 104 11 32.7 (9.7) 57.1 (12.6) 52.4(10.5) 0.858(0.535) 
Other 20 0 40.6(10.8) 58.8(13.6) - ( - ) 0.509 (0.372) 
Female adults 159 11 37.0(12.4) 60.1 (13.1) 61.1(13.7) 0.734(0.589) 
Spondylitis 21 2 42.5(10.7) 64.9(8.5) 66.5(6.5) 0.429 (0.259) 
Tuberculosis 114 8 34.2(11.2) 58.8(13.5) 61.4(14.8) 0.858 (0.632) 
Other 24 1 45.3(13.5) 62.0(13.3) 48.0 (—) 0.414(0.290) 
Juveniles 204 14 11.6(5.3) 37.7(12.6) 33.1(9.9) 1.036 (0.807) 
Boys 105 5 11.6(5.3) 38.8(12.2) 31.0(5.1) 1.095 (0.887) 
Girls 99 9 11.7(5.3) 36.5(12.9) 34.3(11.5) 0.973 (0.707) 
Note. Number of patients included in analysis = 831. Number of patients with cataract = 58 (two before 
treatment: one within 1 year after treatment). Thirty-eight patients excluded from analysis because of 
missing dose information: 30 without follow-up. 
a Mean and standard deviation. 
dylitis patients. The correlation with dosage is not a correlation with the severity of original disease, because 
dosages varied substantially between different clinics and decreased markedly in consecutive years of the 
period when the 224Ra treatment was practiced. 
The principal purpose of the present analysis is to provide the dosage and time association of the inci-
dence of cataracts and to compare the dependence for 224Ra with those for X and y rays. As pointed out, 
most lens opacifications were registered when they had developed far enough to impair vision. It was 
decided, therefore, to utilize, as far as possible, a uniform criterion and to record each cataract at a stage 
when it interfered with vision. A few lens opacifications which happened to be discovered at an early stage 
were accordingly assigned the later dates that corresponded to impaired vision. 
The somewhat loose criteria of impaired vision that had to be used in this study might suggest that in 
some cases cataracts have been misdiagnosed, and that some acuity deficits might have been due to macular 
and other retinal defects. However, this is unlikely because there has been, in almost all cases, confirmation 
by an ophthalmologist of well-progressed cataracts. The major source of uncertainty appears to be merely 
the variability of the times to diagnosis which depended on the patient's perception of impaired vision. 
III. SYNOPSIS OF THE DATA 
Table I represents essential aspects of the data. The categorization is largely identi-
cal to the one in earlier reports (14, 20, 25). 
Adults treated for bone tuberculosis were, on average, somewhat younger and re-
ceived about twice the dosage as adults treated for ankylosing spondylitis. The juve-
niles were mostly treated for tuberculosis and received the highest dosages. 
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FIG. 1. Diagram of ages at injection and dosages, i.e., injected 224Ra activities divided by body weight. 
Each patient is represented by a point. Patients who subsequently developed a cataract are represented by 
a solid dot (cataract before age 54) or by a triangle (diagnosis at age 54 or later). 
The subsequent analysis includes 831 patients of known dosage with follow-up 
times exceeding 1 year. Cataract diagnoses of more than 1 year after treatment were 
reported in 55 cases, among them 25 before age 54. Factors such as sex, duration of 
treatment, or cause of treatment have not been included in the present analysis, since 
we found no indication of an influence of these factors. 
In Fig. 1 each patient is plotted by the dosage received and the age at treatment. 
Patients who subsequently developed a cataract before age 54 are marked by a heavy 
dot. Patients who developed a cataract at a later age are marked by a triangle. 
Figure 2 gives the information in more detail. The abscissa specifies the dosage, 
and the vertical lines connect the age at treatment to the age at diagnosis for those 
patients who developed cataracts. Over a wide range of dosages there were a substan-
tial number of cataracts at higher ages; the early cataracts (before age 54), however, 
occurred predominantly at higher dosages. 
A quantitative assessment of the frequency of patients with cataracts needs to be 
related to the number of patients at risk in the different dosage and age classes. To 
avoid the confusion of too many lines, for each patient without a known cataract the 
vertical line from treatment to the end of observation is replaced by a series of points 
with, on average, one point for each 5 years of observation. In this way one can judge 
the number of patients with cataracts and their age at injection and age at diagnosis 
in relation to the total number of patients at risk. This comparison demonstrates even 
more clearly that cataracts at ages above roughly 55 tend to be distributed nearly 
uniformly among patients in the entire dosage range while the early cataracts oc-
curred predominantly in patients with higher dosages. 
On a first, exploratory level the analysis will be restricted to a follow-up of the 
patients through age 53. The division line is somewhat arbitrary in view of the limited 
data for general populations (29-35) and the unknown influence of the original dis-
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FIG. 2. The 55 patients with cataracts more than 1 year after injection are represented by vertical lines 
from their age at injection to age at diagnosis. The 773 patients without known cataracts are represented 
each by a vertical chain of points from age at injection to death or end of observation, with one point on 
the average per 5 years at risk. The point density in the resulting scatter diagram indicates the relative 
number of patients at risk at a specified age and dosage. 
eases. However, it will be seen that the numerical results are substantially in line with 
a more general analysis that utilizes no cutoff but is, of necessity, more complex. 
Figure 3 affords a visualization of the distribution of early (prior to age 54) cataracts 
in dosage, age at treatment, and time from treatment to diagnosis. The representation 
is largely analogous to that in Fig. 2. The abscissa is again the dosage. The ordinate is 
a temporal scale relative to the time of injection. Each patient with an early cataract 
is represented by a vertical line. The upper part of the line gives the time from injec-
tion to diagnosis; the total length of the line is the age of the patient at diagnosis of 
his cataract. 
One point is plotted in the lower part of the diagram for each patient (heavier dots 
for the patients with cataract) to indicate the distribution of ages at treatment. In the 
upper part of the diagram the same method is used as in Fig. 2, i.e., each line for a 
patient without a reported cataract is replaced by a series of points, with one point 
on the average for each 5 years of follow-up through age 53. 
IV. ANALYSIS IN TERMS OF DOSAGE CLASSES 
The simplest analysis consists of forming several dosage classes and determining 
for these classes the fraction of patients who developed a cataract up to a specified 
time after injection. Figure 4 permits a synopsis of the data for this type of analysis. 
Ages at injection and times to diagnosis are given as heavy dots for those patients 
who developed a cataract; they are superimposed on the distribution of points which 
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FIG. 3. The 25 patients with cataracts before age 54 are represented by vertical lines from their years of 
birth (relative to the year of injection) to the year of diagnosis. The locations of the light and heavy dots 
represent the distributions of age at injection and of time to diagnosis within the range of dosages, respec-
tively. The light points on the lower half of the diagram give the age at 224Ra injection for the patients 
without early cataracts. The scatter diagram in the upper part is analogous to that in Fig. 2. It gives one 
point per 5 years at risk up to age 54 for each patient without early cataract. 
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FIG. 4. Diagram of ages at injection versus time from injection to cataract (heavy dots) or last year of 
observation, up to 1986 (light points), for patients without reported cataracts. Each patient is represented 
by a single point. The broken lines indicate the cut-off at 54 years of age. Left upper panel, all dosages. 
Other panels, specified ranges of dosage. 
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give the age at injection and the total duration of follow-up (to 1986) for those patients 
who have not developed a cataract. The broken lines are inserted to separate the early 
opacifications from those that occurred later. It is evident that the early cataracts, i.e., 
those before the age of 54 (heavy dots below the broken line), occurred predominantly 
in the group of patients treated with higher dosages. The number of early cataracts 
in relation to the average dosages in each class not only shows the strong correlation 
to dosage, but indicates, even in this simple representation, that the correlation is 
not a proportionality, but a threshold-like dependence. This will be quantified in the 
subsequent analysis. 
To obtain dependences on time after treatment in the different dosage classes, one 
needs methods that correct for competing risks, i.e., for the fact that some patients 
are lost from observation during the follow-up. The use of crude estimates could lead 
to results which are biased by differences of the follow-up times in the different dosage 
classes. Therefore, one uses for the analysis, the sum-limit estimate which has, in the 
same collective of patients, been used also for the analysis of bone sarcoma rates 
(27), and which is largely equivalent to the familiar Kaplan-Meier, or product-limit, 
estimate (36, 37). The method has been explained earlier (38, 39). The estimated 
cumulative rates, R(t), (cumulative-hazard rates) are obtained from the formula for 
the sum-limit estimate 
where are the times after treatment when a cataract was diagnosed, and Nt is the 
number of patients with a follow-up time of not less than Patients were removed 
from the analysis at age 54. The summation includes cataracts diagnosed within the 
follow-up time t. 
In view of the limited number of patients and of early cataracts, the cumulative 
rates after treatment are derived only for three different dosage ranges, as shown in 
Fig. 5. There were no early cataracts at dosages below 0.2 MBq/kg. The diagram 
confirms that the estimated cumulative rates increase with dosages in a nonlinear 
fashion. 
For the patients injected as juveniles (Fig. 5, lower panel) there is no indication of 
systematically higher cumulative rates than for all patients (Fig. 5, upper panel). Nor 
is there a recognizable change of the temporal distribution with dosage; the earlier 
occurrence of some cataracts at the higher dose levels may merely reflect the overall 
increased frequencies. The data are consistent with a cumulative incidence that does 
not depend on age at treatment and that exhibits the same time course, apart from a 
dose-dependent factor. These conclusions will next be substantiated by an analysis 
that avoids the arbitrary separation into dosage classes. 
V. ANALYSIS IN TERMS OF THE PROPORTIONAL HAZARDS MODEL 
The results of the comparatively simple analysis in the preceding section are consis-
tent with a proportional hazards model. Such a model postulates that rate factors into 
dependences on time after treatment and dosage, 
(1) 
R(U A) = R(t)(aA + A2)e~{ cA (2) 
where / is the time after treatment, and A is the value of the dosage expressed in 
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FIG. 5. Cumulative rates of cataracts versus time after injection. The curves are obtained from the sum 
limit estimate (Eq. (1)). The three relations correspond to the dosage ranges 0.2 to 0.8 MBq/kg, 0.8 to 1.6 
MBq/kg, and 1.6 MBq/kg and beyond. The numbers of patients (and the numbers of cataracts before age 
54) are 386 (2), 176 (12), and 56 (11) for the three groups in the upper panel, and 89 (2), 76 (6), and 30 (6) 
for the lower panel. Patients are included in the computations up to age 54. 
MBq/kg. Suitable scaling of the so-called baseline function, R(t\ can make the co-
efficient with the linear or the quadratic term in dosage equal to unity. Since the 
quadratic term will be seen to be dominant, its coefficient is set equal to unity. 
The model of Eq. (2) avoids the arbitrary separation into dosage classes. R(t) can 
be any increasing dependence on time; it is determined by a maximum likelihood fit 
to the data. The dosage-dependent term is the familiar linear-quadratic dependence, 
with additional exponential term to account for possible deviations from the linear-
quadratic dependence at larger doses. As far as the dosage dependence is concerned, 
the maximum likelihood fit determines merely the two parameters a and c. At this 
stage of the analysis patients were still considered only through age 53. 
The baseline function and the parameters a and c are derived by maximizing the 
partial likelihood corresponding to Eq. (2). The maximum likelihood solution is ob-
tained by a suitable modification of the algorithm of Cox (36). If, as stated, the dosage 
is expressed in MBq/kg, the optimum likelihood is achieved with c = 0.35 and a 
negative coefficient a = -0 .444 . Although negative values of R(t, A) are, of course, 
meaningless, the solution is admissible because no early cataracts were observed at 
dosages less than a. The dosage dependence corresponding to the estimated parame-
ters a and c is represented in Fig. 6 (dotted curve). The cumulative rate for a dosage 
1 MBq/kg is given in the lower panel of Fig. 7. The estimated dosage dependence is, 
except for the highest dosages, quite close to a dose-squared dependence. The maxi-
mum likelihood solution of this simpler model, 
R(t,A) = R(t)A\ (3) 
is represented in Fig. 6 (solid line) and in the top panel of Fig. 7. The estimated 
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FIG. 6. Cumulative rate of cataracts 30 years after injection according to the proportional hazards models 
with nonparametric time dependence and three different dosage dependences. Solid curve, dose-squared 
model (Eq. (3)); straight line, linear model with threshold (Eq. (5)); dotted curve, linear-quadratic model 
(Eq. (2)). For numerical values of the parameters see Table II. 
coefficients and the likelihood values for the two models are given in Table II. The 
more general model of Eq. (2) must evidently result in a somewhat better likelihood. 
However, the difference in likelihoods is too small to reject the simpler dose-squared 
dosage=1 MBq/kg 
.2 I ' 1 ' 1 r 
0 10 20 30 40 
time after treatment (years) 
FIG. 7. Cumulative rate of cataract versus time after injection with a dosage A = 1 MBq/kg, according 
to the proportional hazards model with the three different dosage dependences: upper panel, dose-squared 
model (Eq. (3)); middle panel, linear model with threshold (Eq. (5)); lower panel, linear-quadratic model 
(Eq.(2)). 
248 CHMELEVSKY ET AL. 
TABLE II 
Analysis in Terms of Proportional Hazards Models 
Values of log-likelihood, L, and parameters 
Age at Number of patients 
treatment (of patients with f(A) = (aA+ A2) Threshold 
(years) cataracts) f(A) = A2 X exp(-cA) (see Eq. (5)) f(A) = Ap 
<21 
204 
(14) 
L = -57.1 L = -56.6 
a = -0.351 
c = 0.292 
L = -56.9 
AT= 0.455 
L = 
P = 
-57 .1 
1.9 
All ages 763 
(25) 
L = -117.4 L = -115.71 
a = -0.444 
c = 0.351 
L= -116.2 
AT =0 .5 
L = 
P = 
-117.4 
2.1 
Note. Follow-up up to age 54; R(t, A) = R(t)-f(A); t, time after injection; A, dosage in MBq/kg. 
model. This is also supported by computations in terms of a model that postulates a 
dependence on dosage with an unspecified exponent, p : 
R(t, A) = R(t)Ap. (4) 
The value of p resulting from the maximum likelihood analysis is very close to 2 (see 
Table II). 
One can go a step further and ask whether the data are equally consistent with a 
linear dependence beyond a dosage threshold, AT. Such a threshold dependence has 
been fitted by Schull and Otake to the observations in the atomic bomb survivors 
(40, 41). The dependence has the form 
fO for A^AT R(t,A) = { (5) 
[R(t)(A-AT) for A>AT. 
The same numerical methods are utilized as with Eqs. (2)-(4) to obtain the maxi-
mum likelihood solution. The result is represented by the dashed line in Fig. 6 and 
the middle panel of Fig. 7. The inferred dosage threshold is AT = 0.5 MBq/kg. At 
twice the threshold, i.e., at dosage A = 1 MBq/kg, the estimated cumulative rate 30 
years after injection lies between 0.08 and 0.1. This agrees roughly with the value 
estimated by Schull and Otake (40, 41) at twice their assumed threshold dose. The 
likelihood achieved with the threshold model is somewhat superior to the likelihood 
achieved with the dose-squared model. This is to be expected since the threshold 
model has one more free parameter than the dose-squared model. The difference in 
the values of the likelihood is not sufficient to reject the dose-squared model in favor 
of the threshold model. Both models afford an adequate representation of the data. 
To detect a possible age dependence of the response, additional computations were 
performed that were restricted to the patients below age 21 at treatment. However, 
as seen in Table II, substantially the same results were obtained, i.e., no age depen-
dence is recognizable in the data. Figure 8 gives the dose dependences for the juve-
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F I G . 8. Cumulative rate of cataract 30 years after injection for patients less than 21 years at injection. 
The relations are derived according to the proportional hazards model with nonparametric time depen-
dence and three different dosage dependences: solid curve, dose-squared model (Eq. (3)); straight line, 
linear model with threshold (Eq. (5)); dotted curve, linear-quadratic model (Eq. (2)). 
niles. Figure 9 gives, in separate panels for juveniles and all patients, the temporal 
dependence of the cumulative rate, R(t\ resulting from the dose-squared model of 
Eq. (3). The absence of a dependence on age at treatment appears to be in general 
agreement with earlier conclusions by Schull and Otake (40, 41). However, such 
agreement depends on the uncertain assumption that absorbed doses to the lens of 
juveniles and adults are equal at equal injected activity per unit body weight. 
dosage = 1 MBq/kg 
.001 l—I 1 ' 1 Ld 1 ' ' 
4 10 40 4 10 40 
time after treatment (years) 
FIG. 9. Cumulative rate of cataracts resulting from the proportional hazards model with dose-squared 
dependence (Eq. (3)) and for an assumed dosage of 1 MBq/kg. The dependence in the right panel (semilog 
plot) is identical to the dependence in the upper panel of Fig. 7 (linear plot). The dashed lines are given for 
comparison. They result from the analysis of all cataracts (see Eq. (6)). 
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VI. MAXIMUM LIKELIHOOD SOLUTION WITH INCLUSION OF ALL OPACIFICATIONS 
An analysis including all cataracts needs to account also for spontaneous cataracts, 
including those that occur at higher age and may or may be not associated with the 
original disease. In the literature data are given either for the frequency of cataract 
surgery (29, 32, 34) or for prevalences determined in slit-lamp examinations of popu-
lation samples at specified ages (33, 35). Cataracts detectable by slit-lamp are more 
numerous than those severe enough to require surgery. The frequencies of age-re-
lated, or disease-related, cataracts in the 224Ra patients must be expected to lie some-
where between. In view of this uncertainty a model was employed that assumes 
merely that lens opacifications unrelated to the 224Ra treatment increase with some 
power of age, 
R(t9A) = [clt]^A2 + [c3{t + T)]'f29 (6) 
where R(t, A) is, in this model, the cumulative rate including both spontaneous and 
treatment-related cataracts. The time after treatment is t, and r is the age at injection, 
so that (/ + r) is the age of a patient at follow-up time t. The first component represents 
the 224Ra treatment-related cataracts. Their cumulative rate is set proportional to the 
square of the dosage and to a power of time after injection. One speaks of Weibull 
models (37) when event rates are assumed to be proportional to a power of time (or 
of some other reference variable). The first term of Eq. (6) is a Weibull model with 
reference to both time after injection and dosage. The second component represents 
the spontaneous cataracts, as a power of age, with a different and, as one infers, sub-
stantially larger exponent. 
For the numerical solution of a Weibull model standard optimization routines are 
sufficient. Equation (6), as a sum of two terms, necessitates somewhat more complex 
procedures. In the present context it is not necessary to deal with details of the algo-
rithm to determine the maximum likelihood values of the four parameters c{,c2,Pi, 
and/?2. 
In Table III results are given for the collective of 831 patients who were followed 
for more than 1 year after injection. The dashed lines in Fig. 9, which represent the 
dose-dependent term in Eq. (6), show that the inferred dosage and time dependence 
agrees well with the results of the previous analysis which has been restricted to ages 
below 54. Figure 10 depicts, for different age cohorts, the total prevalences, including 
the cataracts which are unrelated to treatment (broken curve). 
As a final step the threshold model is considered with inclusion of the age- or dis-
ease-related cataracts 
f [CxtY^A - AT) + [c2(t + r)]p2 for A > AT R(t,A) = \ r c (7) [ [c2(t + T)]^ for A<AT. 
The numerical solution is obtained in analogy to the computations described in 
the preceding sections. Again it is seen that the threshold dependence fits equally well 
as the quadratic dependence. 
Table III also summarizes additional computations which show that the results 
remain largely unchanged when somewhat different subgroups of patients are consid-
ered. The lines labeled "no exclusions" refer to all 861 patients of known dosage, 
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TABLE III 
Analysis in Terms of Weibull Models 
Age at Number of patients injection 
(years) 
(patients with 
cataracts) Cj Pi c2 P2 
Log-
like I ihooc 
Dose-squared model (Eq. (6)) 
All ages 831 (55) 0.0108 2.25a 0.0104 9.7 -334.5 
(±0.003) (±0.36) (±0.0005) (±1.6) 
No exclusions 861 (58) 0.0099 2.12 0.010 7.7 -359.4 
(±0.003) (±0.5) (±0.001) (±1.5) 
Spondylitis 487 (34) 0.0105 2.2 0.0096 9.9 -204.2 
excluded (±0.002) (±0.34) (±0.002) (±1.5) 
Age <21 204(14) 0.0092 2.04 — — -84.3 
Linear model with threshold (Eq. (7)) 
(AT =0.4% MBq/kg) 
All ages 831 (55) 0.0151 2.22 0.0104 9.6 -332.4 
(±0.0024) (±0.4) (±0.0005) (±1.5) 
No exclusions 861 (58) 0.0146 2.02 -0.01 7.9 -358.3 
(±0.003) (±0.6) (±0.001) (±1.5) 
Age <21 204(14) 0.0145 2.1 — — -84.3 
Note. Units: time and age in years, dosage in MBq/kg. Asymptotic standard errors (see (36)) are in 
parentheses. 
a Excludes proportionality (px = 1) with P < 0 . 0 0 1 . 
including those who were followed only briefly after treatment, or who had a cataract 
diagnosed prior to or within 1 year after treatment. Further lines refer to the Weibull 
analysis restricted to those of age below 21 at treatment. Finally, results are given for 
computations excluding all ankylosing spondylitis patients. The results are close to 
those for all patients, and this suggests no substantially higher association of cataracts 
with the original disease in the spondylitis patients. 
FIG. 10. Cumulative rates of cataracts according to the Weibull model in Eq. (6) versus age for patients 
with an assumed dosage of 1 MBq/kg at the ages specified on the graph. The broken curve represents the 
contribution of spontaneous cataracts. 
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VII. DISCUSSION 
The present study is concerned with lens opacifications with impaired vision 
among the 224Ra patients who have been followed by Spiess since their treatment 
several decades ago. The earlier finding (26) of a strong correlation with 224Ra dosage 
has been extended to an analysis of functional dependences on dosage and time after 
treatment. Dosage is expressed as injected activity per body weight. The inferred dos-
age dependence did not appear to depend on age at treatment; the distribution of 
times from 224Ra injections to diagnosis did not recognizably change with dosage or 
age at treatment. This may seem to be in conflict with earlier observations (12, 42, 
43)\ but the failure to see a correlation between dosage and time to diagnosis may be 
due to the limited number of cases and to the uncertainty on how long vision had 
been impaired before some cataracts were reported. 
To make the analysis more transparent, it has been performed in a stepwise fash-
ion. A series of diagrams has first been utilized to relate the diagnoses of severe lens 
opacifications to the number of patients at risk, to the dosage of 224Ra, to the age at 
treatment, and to the age at diagnosis. These diagrams show the strong correlation of 
the incidence of cataracts with dosage. This correlation applies to all ages at treatment 
and equally to the patients whose intended treatment was for tuberculosis and for 
ankylosing spondylitis. It is also seen that the correlation to the injected activity re-
lates predominantly to the cataracts diagnosed at relatively early ages. Diagnoses be-
tween ages 50 to 60 show less correlation with dosage, and diagnoses beyond age 60 
exhibit a correlation predominantly with age. 
On a first, exploratory level of the analysis the patients were considered only up to 
age 54. A linear nonthreshold relationship was strongly rejected (P < 0.001). How-
ever, the data are consistent with either a dependence on the square of the dosage or 
a similar dependence with threshold at 0.5 MBq/kg and a linear dependence beyond 
this threshold. The cumulative incidence of the treatment-related cataracts increases 
approximately as the square of the time after treatment. This type of dependence 
appears to apply regardless of age at injection and regardless of dosage. 
A more general analysis utilizes a maximum likelihood fit of the data for all ages. 
It takes account of a component that is dosage correlated and a component that is 
independent of dosage but is correlated with age. This analysis which relates to all 
58 diagnoses of cataracts yields substantially the same results for the dose-related 
component as was obtained when patients were followed only up to age 54. As shown 
in Table III, the dosage exponent is substantially larger than unity, i.e., simple linear 
proportionality is rejected on a high level of significance. Again one concludes that 
the cumulative rate is equally consistent with a dependence on the square of dosage 
or with a linear dependence on dosage beyond a threshold of 0.5 MBq/kg. 
The same computations, based on the Weibull model, are also applied to subgroups 
of the patients, such as those treated before age 21, or those who did not suffer from 
ankylosing spondylitis. In all of these computations one obtains essentially the same 
result; i.e., the dependence on dosage of injected 224Ra appears to mask whatever 
differences there may be between individual groups of patients. Specifically one can-
not recognize an increased association of lens opacifications with the original disease 
for any of the groups of patients. In view of the overriding correlation with dosage 
this is not surprising, and it does not exclude some degree of such associations. 
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F I G . 11. The cumulative number of cataracts up to the specified calendar year. Step function, observed 
number of cataracts; continuous curves, the expected number of radiation-induced and spontaneous cata-
racts according to the Weibull model (Eq. (6)). 
Figure 11 gives the observed cumulative frequency of cataracts vs calendar year. It 
also gives the partition, according to the maximum likelihood fit, into the dosage 
correlated and the spontaneous cases. Figure 12 gives the analogous information vs 
age. Nearly 400 surviving patients are still in the follow-up, and in view of the present 
results the decision has been made to conduct—during the forthcoming years—a 
systematic examination of those who were treated at younger ages. 
Since there is too little knowledge about the metabolism of 224Ra and the absorbed 
doses to the lens and its surrounding structures, it would be desirable to examine the 
question in animal experiments. In such studies attention would also have to be given 
to a possible influence of the colloidal platinum and eosin which were present in trace 
amounts in most of the 224Ra injections (44). 
The induction of cataracts is conventionally treated as a nonstochastic effect of 
ionizing radiations (45). The results of the present investigation agree with such a 
classification, as far as the threshold-like response is concerned. The inferred thresh-
old of 0.5 MBq/kg lies above the dosage of about 0.15 MBq/kg which is applied 
60 I 1 1 r 
age (years) 
FIG. 12. The cumulative number of cataracts up to the specified age of the 224Ra patients. Step function, 
observed number of cataracts; continuous curves, the expected number of radiation-induced and spontane-
ous opacifications according to the Weibull model (Eq. (6)). 
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in present-day 224Ra treatment of ankylosing spondilitis (46)', the follow-up of 1600 
patients subjected to this treatment has not, up to now, provided evidence of in-
creased frequencies of cataracts (47). 
APPENDIX: CATARACTS IN 224Ra PATIENTS (AUGUST 1986) 
Age at 
1st Time to Age at Injection Radium- Skeletal 
injection diagnosis diagnosis span 224 dosage dose Original 
Patient No. (years) (years) (years) (months) (ßCi/kg) (Gy) disease 
Age* 1 -10 (94 patients, D = 31.5 juCi/kg) 
+ 1114 m 2 2/12 28 30 27 59.0 24.8 TB 
1507 f 3 6/12 37 40 3 28.8 12.1 TB 
1113 m 4 27 31 32 45.9 19.3 TB 
1503 f 4 5/12 10 14 6 15.6 6.6 TB 
1626 f 8 8/12 27 36 19 36.4 15.3 TB 
1619 f 10 5/12 35 45 11 16.7 7.0 TB 
+ 1632 f 107/12 5 15 39 85.7 36.0 TB 
Age 11-20 (110 patients, D = 25.0 ßCi/kg) 
1720 f 147/12 29 43 7 28.3 11.9 TB 
+ 1724 f 156/12 14 30 21 71.9 30.2 TB 
+ 1320 m 15 8/12 15 31 23 35.0 14.7 TB 
1431 m 182/12 6 24 20 110.7 31.0 TB 
+ 1819 f 19 5/12 20 40 11 29.0 8.1 TB 
1825 f 20 4/12 26 46 5 40.3 11.3 TB 
1428 m 20 7/12 20 41 15 48.1 13.5 TB 
Age 21--29 (157 patients, D = 20.2 pCi/kg) 
494 m 21 32 53 27 38.6 5.4 TB 
912 f 21 10 31 8 55.0 7.7 TB 
+895 f 23 30 53 23 38.2 5.4 TB 
469 m 23 25 48 12 24.8 3.5 TB 
505 m 24 11 35 14 50.8 7.1 TB 
880 f 25 32 57 14 30.3 4.2 TB 
913 f 25 36 61 37 55.7 7.8 TB 
974 f 27 21 48 3 28.0 3.9 Arthritis 
344 m 27 28 55 15 27.0 3.8 ANK 
+502 m 27 26 53 25 48.3 6.8 TB 
+475 m 29 6 35 11 27.6 3.9 TB 
294 m 29 28 57 3 16.2 2.3 ANK 
157 m 29 37 66 2 7.6 1.1 ANK 
Age 30-39 (178 patients, D = 12.2 pCi/kg) 
+416 m 30 24 54 ? 6.8 1.0 TB 
499 m 32 37 69 20 42.8 6.0 TB 
7 m 32 24 56 1 1.6 0.2 ANK 
(315) m 32 0 32 5 19.8 2.8 ANK 
449 m 34 26 60 8 17.6 2.5 TB 
+486 m 35 17 52 19 34.3 4.8 TB 
889 f 35 33 68 16 36.0 5.0 TB 
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Age at 
1st Time to Age at Injection Radium- Skeletal 
injection diagnosis diagnosis span 224 dosage dose Original 
Patient No. (years) (years) (years) (months) (ßCi/kg) (Gy) disease 
Age 30 -39 (178 patients, D = 12.2 /uCi/kg) 
704 f 37 23 60 1 5.0 0.7 ANK 
+353 m 37 10 47 11 52.0 7.3 ANK 
879 f 38 37 75 7 28.8 4.0 TB 
77 m 39 25 64 ? 4.4 0.6 ANK 
102 m 39 33 72 1 4.8 0.7 ANK 
Age 40-49 (185 patients, D = 12.2 ^Ci/kg) 
+ 5 0 m 41 0 41 4 4.0 0.6 ANK 
+329 m 41 26 67 10 22.8 3.2 ANK 
189 m 42 28 70 2 8.8 1.2 ANK 
297 m 42 22 64 5 17.5 2.5 ANK 
+28 m 42 16 58 1 3.2 0.5 ANK 
721 f 42 31 73 3 30.0 4.2 ANK 
848 f 43 30 73 ? 14.5 2.0 TB 
+506 m 44 5 49 22 53.8 7.5 TB 
149 m 44 16 60 1 6.8 1.0 ANK 
32 m 45 31 76 2 3.2 0.5 ANK 
78 m 47 23 70 5 4.4 0.6 ANK 
+442 m 49 19 68 7 16.0 2.2 TB 
Age 50+ over (107 patients, D = 12.3 /xCi/kg) 
111 m 50 11 61 3 4.8 0.7 ANK 
+868 f 52 26 «78 6 23.0 3.2 TB 
73 m 53 29 82 2 4.0 0.6 ANK 
+ 162 m 56 17 73 1 8.0 1.1 ANK 
+299 m 57 24 81 5 17.6 2.5 ANK 
+52 m 58 2 60 1 4.0 0.6 ANK 
(12) m 59 0 59 ? 2.0 0.3 ANK 
Note. +, Deceased; TB, tuberculosis; ANK, ankylosing spondylitis; m, male; f, female. Patient records 
are in traditional units of activity. To convert to SI units, 1 ßCi/kg = 37 mBq/kg. 
* Age at first injection. 
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